Consumer trial demonstrates rapid axillary malodor reduction and microbiome preservation in humans, highlighting the potential of targeted lysins for personal care.
Key Points
To evaluate the safety and efficacy of a recombinant bacteriophage lysin in reducing axillary malodor and to determine its impact on skin microbiome diversity.
Conducted a human consumer trial to test the deodorizing efficacy of a proprietary recombinant lysin.
Performed supportive in vitro and in vivo safety evaluations along with skin microbiome profiling.
Application of the recombinant lysin produced rapid and sustained reduction in axillary malodor (numerical effect sizes not reported).
Treatment caused no skin irritancy and successfully preserved overall skin microbiome diversity.